Keymed Biosciences Inc. (HKG:2162)

Hong Kong · Delayed Price · Currency is HKD

72.50

-2.75 (-3.65%)

Jul 30, 2026, 3:40 PM HKT

14.90% (1Y)

Market Cap	22.17B +19.3%
Revenue (ttm)	797.12M +67.3%
Net Income	-581.60M
EPS	-2.12
Shares Out	294.60M
PE Ratio	n/a
Forward PE	29.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,969,478
Open	76.90
Previous Close	75.25
Day's Range	71.15 - 76.90
52-Week Range	44.66 - 89.75
Beta	-0.15
Analysts	Strong Buy
Price Target	96.12 (+32.58%)
Earnings Date	Aug 24, 2026

About Keymed Biosciences

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors; CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 1,625

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2162

Full Company Profile

Financial Performance

In 2025, Keymed Biosciences's revenue was 716.31 million, an increase of 67.31% compared to the previous year's 428.12 million. Losses were -522.64 million, 1.44% more than in 2024.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 13 analysts, the average rating for 2162 stock is "Strong Buy." The 12-month stock price target is $96.12, which is an increase of 32.58% from the latest price.

Price Target

$96.12

(32.58% upside)

Analyst Consensus: Strong Buy

Stock Forecasts